CHD1Li-enhanced Chemotherapy for Colorectal Cancer
Official title: CHD1Li Targeted Combinations with Chemotherapy to Address Unmet Needs in Colorectal Cancer Treatment
Funded at Onconaut Therapeutics INC. · NIH-11457447 · Data updated 2026-11-12
A new treatment approach combines standard chemotherapy with CHD1L inhibitors to help people with colorectal cancer respond better to therapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Onconaut Therapeutics INC. NIH-funded |
| Lab location | 1 site (Aurora, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $760,110 |
| NIH project number | 4R42CA306378-02 |
| Project ID | NIH-11457447 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with advanced/metastatic colorectal cancer who are candidates for FOLFIRI-based therapy.
✕Less likely to help
Patients whose tumors do not rely on CHD1L pathways or who cannot tolerate combination therapy may not benefit.
What this research studies
This grant explores using CHD1Li together with the standard FOLFIRI regimen (folinic acid, 5-FU, irinotecan) and bevacizumab to potentially reduce tumor growth and improve responses in advanced colorectal cancer. The approach targets CHD1L, a chromatin-remodeling protein linked to cancer progression and resistance, to make cancer cells more vulnerable to chemotherapy and other targeted drugs. The project involves preclinical studies that may include cell models and animal systems to understand how CHD1L inhibition changes tumor behavior and treatment sensitivity. If successful, these findings could inform future clinical testing and help tailor combination therapies for patients with difficult-to-treat tumors.
Why it matters
Potential benefit: If successful, the approach could improve response rates and survival for patients with advanced colorectal cancer.
How similar studies have gone: Existing research suggests combining chemotherapy with targeted chromatin-modifying strategies can enhance efficacy in some cancers, but clinical data in colorectal cancer are still emerging.
Where this research is happening
-
Onconaut Therapeutics INC.
Aurora, United States Active
Researchers
- Principal investigator: Labarbera, Daniel V. — Onconaut Therapeutics INC.
- Study coordinator: Labarbera, Daniel V.
Related research
Other NIH-funded projects on the same topics.
-
3D lab model of tiny colorectal cancer spots in the liver to test post-surgery chemotherapy
The project creates 3D liver models with tiny colorectal cancer metastases to test which chemotherapy drugs might help prevent recurrence after surgery.
-
Creating a 3D model to test treatments for colorectal cancer that has spread to the liver
This study is creating a special 3D model of the liver to help find better treatments for colorectal cancer that has spread there, using real patient cells to test different chemotherapy options that could target hidden cancer cells.
-
Improving colorectal cancer screening and follow-up care.
This study is working to help more people get screened for colorectal cancer and receive the follow-up care they need, especially those who haven't been screened much before, so that everyone can have better access to important health checks and improve their overall health.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Colorectal cancer prognosis through a broad, collaborative study
A large, multi-center study follows people newly diagnosed with colorectal cancer to find biomarkers and patterns that predict outcomes and guide future care.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.